Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection

Bibliography

• KMohd Hanafiah, JGroeger, ADFlaxman, STWiersma. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333–42
   PubMed Web of Science ®Google Scholar
• PSimmonds, JBukh, CCombet, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42(4):962–73
   PubMed Web of Science ®Google Scholar
• JMedrano, KNeukam, NRallon, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010;51(10):1209–16
   PubMed Web of Science ®Google Scholar
• VSoriano, EVispo, PLabarga, et al. Viral hepatitis and HIV co-infection. Antiviral Res 2010;85(1):303–15
   PubMed Web of Science ®Google Scholar
• PTuma, JMedrano, SResino, et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 2010;15(6):881–6
   PubMed Web of Science ®Google Scholar
• VSoriano, MPuoti, MSulkowski, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21(9):1073–89
   PubMed Web of Science ®Google Scholar
• JMassard, VRatziu, DThabut, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44(1 Suppl):S19–24
   PubMed Web of Science ®Google Scholar
• NQurishi, CKreuzberg, GLuchters, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362(9397):1708–13
   PubMed Web of Science ®Google Scholar
• JPAnderson, EJTchetgen, VLo Re, et al. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 2014;58(5):719–27
   PubMed Web of Science ®Google Scholar
• FPoordad, DDieterich. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012;19(7):449–64
   PubMed Web of Science ®Google Scholar
• FPoordad, JMcConeJr, BRBacon, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195–206
   PubMed Web of Science ®Google Scholar
• IMJacobson, JGMcHutchison, GDusheiko, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405–16
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61(2):373–95
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA/IAS–USA. Recommendations for testing managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org [Accessed 24 April 2014]
   Google Scholar
• RWeber, CASabin, NFriis-Moller, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166(15):1632–41
   PubMed Web of Science ®Google Scholar
• DLThomas, JAstemborski, RMRai, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284(4):450–6
   PubMed Web of Science ®Google Scholar
• FJTorriani, MRodriguez-Torres, JKRockstroh, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438–50
   PubMed Web of Science ®Google Scholar
• MSSulkowski, YBenhamou. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007;14(6):371–86
   PubMed Web of Science ®Google Scholar
• SWWorm, NFriis-Moller, MBruyand, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010;24(3):427–35
   PubMed Web of Science ®Google Scholar
• JVFernandez-Montero, VSoriano. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol 2012;26(4):517–30
   PubMed Web of Science ®Google Scholar
• VSoriano, IMaida, MNunez, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004;9(6):987–92
   PubMed Web of Science ®Google Scholar
• VSoriano, PLabarga, ARuiz-Sancho, et al. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006;20(17):2225–7
   PubMed Web of Science ®Google Scholar
• ELissen, NClumeck, RSola, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006;20(17):2175–81
   PubMed Web of Science ®Google Scholar
• JBerenguer, JAlvarez-Pellicer, PMMartin, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50(2):407–13
   PubMed Web of Science ®Google Scholar
• MSulkowski, SPol, JMallolas, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13(7):597–605
   PubMed Web of Science ®Google Scholar
• DTDieterich, VSoriano, KESherman, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV-co-infected patients: SVR12 interim analysis. 19th Conference on Retroviruses and Opportunistic Infections, USA, Seattle, WA; March 5 - 8, 2012; 2012
   Google Scholar
• DDieterich, JRockstroh, COrkin, et al. Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: a Phase 3 Study. Clin Infect Dis. 2014;59(11):1579–87
   Google Scholar
• JMolina, COrkin, DIser. All-oral therapy with SOF plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2)[abstract MOAB0105LB]. 20th International AIDS Conference; Melbourne; 2014
   Google Scholar
• DDieterich, CTural, MNelson. Faldaprevir plus pegylated interferon alfa-2a/RBV in HIV/HCV coinfection: STARTVerso4[abstract 23]. Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston; 2014
   Google Scholar
• MSulkowski, JEron, DWyles. TURQUOISE-I: safety and efficacy of ABT-450/r/ombitasvir, dasabuvir, and RBV in patients co-infected with hepatitis C and HIV-1 [abstract MOAB0104LB]. 20th International AIDS Conference; Melbourne, Australia; 2014
   Google Scholar
• AOsinusi, KTownsend, ANelson. Use of SOF/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV [abstract 14]. 49th Annual Meeting of the European Association for the Study of the Liver; London, England; 2014
   Google Scholar
• MSulkowski, JMallolas, SPol, et al. Efficacy and safety of the all-oral regimen, mk-5172/mk-8742 +/− rbv for 12 weeks in gt1 hcv/hiv co-infected patients: THE C-WORTHY STUDY. J Hepat 2014;60(1):S26
   Google Scholar
• MSulkowski, MRodriguez-Torres, JLalezari. All-Oral Therapy with SOF Plus Ribavirin for the treatment of HCV genotype 1,2 and 3 infection in patients coinfected with HIV (PHOTON-1). AASLD Annual Meeting 2013; Washington, DC; 2013
   Google Scholar
• MPLe, AGervais, CLe Beller, et al. Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir. J Antimicrob Chemother 2013;68(5):1208–9
   PubMed Web of Science ®Google Scholar
• ERCachay. Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man. Clin Infect Dis 2013;56(1):163–4
   PubMed Web of Science ®Google Scholar
• MSSulkowski, KESherman, DTDieterich, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159(2):86–96
   PubMed Web of Science ®Google Scholar
• SNaggie, MSSulkowski. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012;142(6):1324–34; e3
   PubMed Web of Science ®Google Scholar
• EPoveda, EVispo, PBarreiro, et al. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. Antivir Ther 2012;17(3):571–5
   PubMed Web of Science ®Google Scholar
• KESherman, SLFlamm, NHAfdhal, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014–24
   PubMed Web of Science ®Google Scholar
• CHezode, CDorival, FZoulim, et al. Safety of TPV or boceprevir in combination with peginterferon alfa/ribavirin in cirrhotic non-responders. First results of the French National Early Access Program: (ANRS CO20-CUPIC). J Hepatol 2012;56(Suppl 2):abstract 8
   Google Scholar
• MRodriguez-Torres, JSlim, LBhatti, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012;13(3):142–52
   PubMed Web of Science ®Google Scholar
• LCotte, JBraun, CLascoux-Combe, et al. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014;59(12):1768–76
   PubMed Web of Science ®Google Scholar
• JMallolas, SPol, ARivero, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected Patients: end of treatment (week-48) interim results. 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; 2012
   Google Scholar
• PYKwo, EJLawitz, JMcCone, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376(9742):705–16
   PubMed Web of Science ®Google Scholar
• Evaluating the effectiveness of boceprevir, pegylated-interferon alfa 2b and ribavirin in treating hepatitis C virus (HCV) infection in adults with HIV and HCV infection. ClinicalTrials.gov Identifier: NCT01482767 Available from: https://clinicaltrials.gov/ct2/show/NCT01482767?term=NCT01482767&rank=1
   Google Scholar
• IRosa. Management of side-effects. Clin Res Hepatol Gastroenterol 2011;35(Suppl 2):S69–74
   PubMedGoogle Scholar
• MSSulkowski, SNaggie, JLalezari, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312(4):353–61
   PubMed Web of Science ®Google Scholar
• MRodriguez-Torres, JRodriguez-Orengo, AGaggar. SOF and peginterferon alfa-2a/ribavirin for treatment-naıve genotype 1−4 HCV infected patients who are HIV coinfected with HIV[abstract 714. Infectious Diseases Week; Philadelphia, PA; 2013
   Google Scholar
• IJacobson, RGhalib, MRodriguez-Torres. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. Special Issue: the 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013. Hepatology 2013;58(4):1379A
   Google Scholar
• CTural, JRockstroh, MNelson. Impact of baseline variables on response to faldaprevir plus pegylated interferon alpha-2a and RBV in patients with HIV/HCV genotype-1 coinfection in a phase III trial [abstract Su1055]. Digestive Disease Week (DDW 2014); Chicago; 2014
   Google Scholar
• JMallolas, MBattegay, JGuardiola. Comparison of 24 and 48 Weeks of Treatment With Faldaprevir and Pegylated Interferon/RBV in Patients With Detectable but Not Quantifiable HCV RNA At Week 4 [abstract Su1052]. Digestive Disease Week (DDW 2014); Chicago; 2014
   Google Scholar
• JRockstroh, MValantin, JMallolas, et al. Pharmacokinetics of faldaprevir and antiretrovirals in patients with HIV/HCV co-infection. 21st Conference on Retroviruses and Opportunistic Infections; Boston; 2014
   Google Scholar
• MSSulkowski, IMJacobson, DRNelson. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014;370(16):1560–1
   PubMed Web of Science ®Google Scholar
• Phase III HIV/HCV co-infection daclatasvir (DCV)+ sofosbuvir (SOF) (ALLY 2). ClinicalTrials.gov. NCT02032888 Available from: https://clinicaltrials.gov/ct2/show/NCT02032888
   Google Scholar
• Safety, tolerability, and efficacy of asunaprevir and daclatasvir in subjects coinfected with HIV-HCV. ClinicalTrials.gov Identifier: NCT02124044 Available from: https://clinicaltrials.gov/ct2/show/NCT02124044
   Google Scholar
• Merck’s Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection. 2014 3/5/14 Available from: http://www.mercknewsroom.com/news-release/research-and-development-news/mercks-investigational-hepatitis-ctreatment-regimen-mk-5; Merck Newsroom Home, Wednesday, March 5, 2014 4:15 pm EST, Boston
   Google Scholar
• JJKiser, JRBurton, PLAnderson, GTEverson. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012;55(5):1620–8
   PubMed Web of Science ®Google Scholar
• DEKarageorgopoulos, OEl-Sherif, SBhagani, SHKhoo. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014;27(1):36–45
   PubMed Web of Science ®Google Scholar
• RVan Heeswijk, VGard, GBoogaerts. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [abstract A1-1738a]. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy;. Chicago, IL; 2011
   Google Scholar
• RVan Heeswijk, AVandevoorde, GBoogaerts. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2011
   Google Scholar
• CKasserra, EHughes, MTreitel. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2011
   Google Scholar
• VGarg, GChandorkar, YYang, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013;75(2):431–9
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Podcast for Healthcare Professionals: updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs. Available from: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm302136.htm [21 April 2012]
   Google Scholar
• EHulskotte, HFeng, FXuan, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Clin Infect Dis 2013;56(5):718–26
   PubMed Web of Science ®Google Scholar
• JKiser, DLu, SRosenkranz. Boceprevir and antiretroviral pharmacokinetic interactions in HIV/HCV coinfected persons – AIDS clinical trials group study A5309S. HCV Interaction Studies presented at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington; 2014
   Google Scholar
• SOuwerkerk-Mahadevan, VSekar, MPeeters, MBeumont-Mauviel. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with RPV, TDF, EFV, or RAL in health volunteers[abstract 49]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, Washington; 2012
   Google Scholar
• BKirby, AMathias, SRossi. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association of the Study of Liver Diseases (AASLD) 2012; Boston, MA; 2012
   Google Scholar
• HARVONI(ledpasvir and sofosbuvir). US FDA approved product information. Available from: http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
   Google Scholar
• PGerman. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [Abstract O_06]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington; 2014
   Google Scholar
• MNelson, KArasteh, MJain, et al. Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV/HCV co-infection. 21st Conference on Retroviruses and Opportunistic Infections(CROI 2014); Boston; 2014
   Google Scholar
• VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). US FDA approved product information. Available from: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf
   Google Scholar
• AKhatri, HWang, TWang, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with emtricitabine+tenofovir, raltegravir, rilpivirine and efavirenz. The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 5 – 9 Sep 2014; Washington, DC
   Google Scholar
• WYeh, WMarshall, EMangin, et al. Pharmacokinetic interactions between HCV NS5A inhibitor MK-8742 and efavirenz [abstract 498]. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston; 2014
   Google Scholar
• WYYeh, WMarshall, JMa, et al. Ritonavir-boosted atazanavir, lopinavir and darunavir increase HCV NS5A inhibitor MK-8742 levels [abstract 638]. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston; 2014
   Google Scholar
• LCaro, JETalaty, ZGou, et al. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers [abstract 487]. 64th AASLD annual meeting; Washington; 2013
   Google Scholar
• WYeh, IPFraser, LCaro, et al. No meaningful PK interaction between HCV protease inhibitor MK-5172 and tenofovir or raltegravir [abstract 500]. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston; 2014
   Google Scholar
• JETalaty, LCaro, WWYeh, et al. Pharmacokinetic interactions between HCV NS5A inhibitor MK-5172 and efavirenz in normal healthy volunteers [abstract 492]. 64th AASLD annual meeting; Washington; 2013
   Google Scholar
• JPZarski, BBohn, ABastie, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28(1):27–33
   PubMed Web of Science ®Google Scholar
• SDCrockett, EBKeeffe. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005;4:13
   PubMedGoogle Scholar
• CJChu, SDLee. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008;23(4):512–20
   PubMed Web of Science ®Google Scholar
• SNaggie, MSulkowski, JLalezari. Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV coinfected patients (PHOTON-1)[abstract 26]. 21st Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts; 2014
   Google Scholar
• JJKiser, JRBurton, GTEverson. Drug–drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596–606
   PubMed Web of Science ®Google Scholar
• RTeixeira, ANascimento Yde, DCrespo. Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz J Infect Dis 2013;17(2):194–204
   PubMed Web of Science ®Google Scholar